<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346889</url>
  </required_header>
  <id_info>
    <org_study_id>2017/765 C</org_study_id>
    <nct_id>NCT03346889</nct_id>
  </id_info>
  <brief_title>Vestibular Outcomes in Vestibular Schwannoma</brief_title>
  <acronym>VOVS</acronym>
  <official_title>Vertigo Symptoms, Balance and Vestibular Function in Patients With Vestibular Schwannoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have shown that vertigo is the symptoms that mostly affect quality of life
      in patients with vestibular schwannoma. There is still limited knowledge as to why some
      patients with this disorder develop vertigo, while others with the same diagnosis do not. The
      purpose of this study is to measure symptom-related quality of life and to relate this to
      objective disease characteristics at baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a longitudinal observational study with data collected at baseline and after
      treatment.

      Variables collected at baseline include age, sex, tumor size, location, type (cystic/solid),
      tumor side, symptom variables including Dizziness Handicap Inventory, Vertigo Symptom Scale
      Short Form, Haukeland Dizziness Questionnaire, Visual analog scale, Hospital Anxiety and
      Depression Scale, RAND-12, dynamic posturography, video-based head impulse test, bithermal
      caloric tests, ocular and cervical vestibular evoked myogenic potentials.

      Follow-up data after 1 year are the same patient-reported outcomes as at baseline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Dizziness Handicap Inventory (DHI)</measure>
    <time_frame>Baseline and 1-year follow-up</time_frame>
    <description>25-item symptom score 0 - 100 points on dizziness handicap severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vertigo Symptom Scale Short Form</measure>
    <time_frame>Baseline and 1-year follow-up</time_frame>
    <description>15-item symptom score 0 - 60 points on vertigo symptom quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haukeland Dizziness Questionnaire (HDQ-10)</measure>
    <time_frame>Baseline and 1-year follow-up</time_frame>
    <description>10-item symptom score 0 - 30 points on vertigo symptom severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vertigo Visual Analog Scale</measure>
    <time_frame>Baseline and 1-year follow-up</time_frame>
    <description>100 mm visual analog scale on vertigo symptom severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Baseline and 1-year follow-up</time_frame>
    <description>14-item anxiety and depression score 0 - 42 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAND-12</measure>
    <time_frame>Baseline and 1-year follow-up</time_frame>
    <description>12-item health-related quality of life score</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Vestibular Schwannoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients in Norway with newly diagnosed vestibular schwannoma (VS) are referred to
        Haukeland University Hospital for evaluation. The size of the study population therefore
        depends on the incidence of VS in Norway and the inclusion period. The incidence of VS in
        Norway is approximately 150 per year in a population of 5.2 million.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients living i Norway referred to Haukeland University Hospital due to newly
             diagnosed, untreated vestibular schwannoma

        Exclusion Criteria:

          -  Inability to undergo test protocol due to physical or language barriers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederik K Goplen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederik K Goplen, PhD</last_name>
    <phone>+4755975000</phone>
    <email>frederik.goplen@helse-bergen.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathrin K Nilsen, MD</last_name>
    <phone>+4755975000</phone>
    <email>kathrin.skorpa.nilsen@helse-bergen.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <state>Hordaland</state>
        <zip>5009</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederik Goplen, PhD</last_name>
      <phone>+4755975000</phone>
      <email>frederik.goplen@helse-bergen.no</email>
    </contact>
    <contact_backup>
      <last_name>Kathrin S Nilsen, MD</last_name>
      <phone>+4755975000</phone>
      <email>kathrin.skorpa.nilsen@helse-bergen.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vestibular evoked myogenic potentials</keyword>
  <keyword>head impulse testing</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurilemmoma</mesh_term>
    <mesh_term>Neuroma, Acoustic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

